The healthcare stock has hit multi-year highs this year amid positive results from its personalized cancer vaccine.
Axsome's revenue has climbed about 54% while Moderna's net losses run deep, but a steep valuation gap may tip the scales for ...
The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%.
Moderna promised 20% sales growth in 2026 -- but Wall Street wants 24%.
Moderna also provided updates on commercial growth, oncology pipeline progress, manufacturing readiness and mid-term ...
Key TakeawaysModerna shares fell 7% today after the company guided to cash costs of about $4 billion in 2027 and $4 billion ...
A single dose of Moderna's mResvia RSV vaccine was 60.3% protective against documented respiratory syncytial virus (RSV) ...
One stock has soared more than sevenfold this year, another just lost a quarter of its value on leaked data, and a third ...
A US appeals court on Thursday grappled ​with how a federal law shielding companies from patent claims over products made for the government applies to ‌a dispute over Moderna's COVID-19 vaccines that ...
From the 19th to the 24th, the program *Chosun Ilbo Money* will deliver diverse economic and lifestyle information, covering ...
Real-world analysis of more than 294,000 U.S. Veterans aged 65 and older found mNEXSPIKE was associated with a 35.9% ...
CAMBRIDGE, MA / ACCESS Newswire / November 10, 2026 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in ...